MabGenesis Inc. is a biopharmaceutical startup that provides first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and companion animals using 30+ years of academic antibody research.
We have the world’s highest quality antibody libraries (MOURA Libraries) in terms of functionality and completeness, and highly efficient monoclonal antibody isolation technology (IMPACT). By using these innovative platform technologies, we provide pharmaceutical companies with unique opportunities for discovery and development of 100% species-specific, therapeutic monoclonal antibodies.
MabGenesis is focused on human and animal antibody pharmaceutical business.
In human pharmaceutical area, MabGenesis is committed to obtain innovative therapeutic antibodies to meet unmet medical needs, especially, cancer and zoonotic diseases.
In animal pharmaceutical area which is rapidly growing, MabGenesis has already established canine and feline MOURA antibody libraries that allow for the discovery of high-quality 100% canine and 100% feline antibodies for the treatment of various diseases. Our goal is to be a global innovator in animal antibody therapeutics.
US$ 6 billion* (2032) | A new and large market will emerge * New markets for internal organ diseases, such as chronic kidney disease and enteropathy, may be added.
US$ 250 billion (2023)
An antibody drug is a drug that utilizes an antibody that exists in a living body. By selectively binding to target molecules (antigens), antibody drugs perform various pharmacological effects.
The antibody drug market is expected to exceed 14 trillion yen in 2020, and “fully human antibodies”, which are expected to have higher efficacy and safety in the future, have become the mainstream of antibody drugs.
In the future, with the aging of companion animals (dogs and cats), it is expected that the market for complete dog/cat antibodies, which are more effective and safer for pets, will increase.
